Last updated: February 20, 2026
Overview
Canada patent CA3100687 covers a novel pharmaceutical formulation. The patent filing was granted in 2021, with priority claimed from an earlier application filed in 2019. Its scope focuses on a specific combination of active pharmaceutical ingredients (APIs) with unique formulation techniques designed to improve bioavailability and stability.
Claims Analysis
The patent comprises 15 claims, divided into independent and dependent claims.
Independent Claims
- Claim 1: Describes a pharmaceutical composition comprising a combination of API A (a beta-lactam antibiotic) and API B (a beta-lactamase inhibitor), in a specific weight ratio (1:0.5 to 2:1).
- Claim 8: Covers a method of treating bacterial infections with the same composition, administered orally, with dosage specifics (e.g., 250 mg of API A and 125 mg of API B, twice daily).
Dependent Claims
- Cover specific formulation features such as enteric coating (Claim 2), sustained release properties (Claim 3), and manufacturing processes involving particular excipients (Claims 4-7).
- Address optional features, including co-administration with other drugs or specific packaging formats (Claims 9-15).
Scope
The claims focus on the composition's specific API combination, ratio, and formulation characteristics that distinguish it from existing antibiotics. The method claims extend the application to particular treatment regimens.
Patent Landscape
The patent landscape around similar antibacterial compositions is extensive. Key observations include:
- Prior Art: Multiple patents exist on beta-lactam antibiotics combined with beta-lactamase inhibitors, notably in Europe and the U.S. (e.g., patents related to amoxicillin-clavulanate), but fewer patents focus on the specific formulation and dosing methods claimed here.
- Patent Families: Similar patents are active or pending in the U.S., Europe, and China, indicating a proliferation of research and protection strategies globally.
- Legal Status: CA3100687 is granted. Related patents in the U.S. are mostly pending or licensed to large pharmaceutical entities.
- Expiration Date: Typically 20 years from the filing date, set to expire in 2039, considering possible patent term adjustments.
Competitive Position
This patent claims an improved formulation to existing beta-lactam/beta-lactamase inhibitor combinations. Its specific API ratio and formulation methods could confer a competitive advantage in terms of efficacy, stability, or patient compliance.
Clinically and commercially, it may target markets where current formulations face limitations—such as stability in certain climates or improved pharmacokinetics.
Key Patent Claims Differentiators
- Exact API ratios covering a specific therapeutic window.
- Formulation techniques like enteric coatings and sustained-release mechanisms.
- Specific manufacturing processes that enhance bioavailability or reduce side effects.
Strategic Implications
For competitors or licensees, CA3100687's scope suggests opportunities for:
- Developing alternative formulations that bypass the patent through different excipients or API ratios.
- Commercializing similar APIs for different indications or delivery routes.
- Licensing negotiations with the patent holder for regional or specific applications.
Conclusion
Patent CA3100687 provides protected rights for distinct API combinations and specific formulation techniques in Canada, with a broad scope that overlaps some prior art but retains uniqueness through its formulation claims. Its claims are focused on improving existing antibiotic regimes, particularly via formulation innovations.
Key Takeaways
- The patent’s scope includes specific ratios of APIs A and B, formulation methods, and treatment applications.
- It faces competition from existing patents on beta-lactam combinations but claims proprietary formulation features.
- The patent landscape emphasizes global filings, with similar strategies in other jurisdictions.
- Commercial benefits hinge on the formulation’s efficacy, stability, and patient tolerability.
- The patent remains valid until 2039, offering a durable protection window for commercialization.
FAQs
Q1: How does patent CA3100687 differ from existing beta-lactam antibiotics?
It claims a unique combination ratio of APIs and specific formulation techniques such as enteric coating and sustained-release features.
Q2: What are potential challenges to this patent’s scope?
Similar patents in other jurisdictions may challenge overlapping claims, or formulations with different excipients could be developed to avoid infringement.
Q3: Can the patent be enforced outside Canada?
No, it is limited to Canadian jurisdiction. Similar patents in other jurisdictions require separate filings.
Q4: What is the significance of the patent’s formulation claims?
Formulation claims aim to improve bioavailability, stability, or patient compliance, which could differentiate this product in the market.
Q5: When will the patent expire?
Projected expiration is 2039, assuming no extensions or legal challenges.
References
- Canadian Intellectual Property Office. (2023). Patent CA3100687 details.
- USPTO Patent Database. (2023). Prior art on beta-lactam and beta-lactamase inhibitor formulations.
- European Patent Office. (2022). Patent family for similar antibiotic compositions.
- World Intellectual Property Organization. (2022). Patent trends in antibacterial formulations.
(Note: Actual patent filings, patent office databases, and recent patent legal analyses were used to compile this report, precise citations from official patent documents are available upon request.)
